Berkeley Lights, Inc. (BLI), a leader in digital cell biology, closed a $95 million financing round led by Nikon and backed by existing investors Sequoia Capital, Walden-Riverwood Ventures, Black Diamond Ventures, and Paxion Capital. New investors Cota Capital, KTB Network, Atinum Investment, Shangbay Capital, AJS BioTree Healthcare Fund, and Varian also participated in the round.
BLI developed a unique nanoscale technology designed to accelerate drug discovery and development processes through bioscience, technology, and information. The company plans to use the funds to expedite solutions for cell therapy development and manufacturing, including CAR T and endogenous T-cells, as well as increase research and development and expansion of commercial activities.